Subscribe
shutterstock_1384219187_picturedesignswiss
PictureDesignSwiss / Shutterstock.com
28 February 2020AmericasSarah Morgan

Biogen blocking bid rejected; signs $2.4bn deal

The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Mylan scores multiple sclerosis patent win over Biogen
23 June 2020   Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Big Pharma
Pharma company fails to block €140m licence payment
23 June 2021   Taiwanese pharmaceutical company PharmaEssentia Corporation has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Mylan scores multiple sclerosis patent win over Biogen
23 June 2020   Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Big Pharma
Pharma company fails to block €140m licence payment
23 June 2021   Taiwanese pharmaceutical company PharmaEssentia Corporation has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals.

More on this story

Americas
Mylan scores multiple sclerosis patent win over Biogen
23 June 2020   Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Big Pharma
Pharma company fails to block €140m licence payment
23 June 2021   Taiwanese pharmaceutical company PharmaEssentia Corporation has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool